Supplementary Table S11

Patient characteristics by Ki67 status in the Stockholm cohort (n= 113, missing: 46)

Characteristic	Ki67 <8% n (%)	Ki67 ≥8% n (%)
	42 (37)	71 (63)
ER		
Positive	39 (93)	55 (77)
Negative	3 (7)	16 (23)
PR		
Positive	32 (76)	49 (69)
Negative	10 (24)	22 (31)
Mean age	58	58
Tumour size		
<20 mm	17 (40)	30 (43)
≥20 mm	25 (60)	40 (57)
Missing cases: 1		
Elston grade		
I	18 (45)	7 (10)
II	21 (53)	26 (38)
III	1 (2)	35 (52)
Missing cases: 5		
Nodal status		
Negative	24 (57)	43 (61)
Positive	18 (43)	28 (39)
Systemic adjuvant therapy*		
None	5 (12)	19 (27)
Endocrine	32 (76)	38 (54)
Chemotherapy	1 (2)	6 (8)
Both	4 (10)	8 (11)
PAM50 subtype		
Basal	2 (5)	10 (14)
ERBB2	1 (2)	8 (11)
Luminal A	27 (64)	15 (21)
Luminal B	4 (10)	29 (41)
Normal-like	8 (19)	9 (13)

*Endocrine or Chemotherapy refers to each treatment alone or in combination with radiotherapy, Both refers to a combination of endocrine treatment and chemotherapy.